A phase I trial of EBI-031 for uveitis
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2016
At a glance
- Drugs EBI 031 (Primary)
- Indications Uveitis
- Focus Adverse reactions
- 07 Jul 2016 According to an Eleven Biotherapeutics media release, the company's Investigational New Drug (IND) application for EBI-031 for treatment of ocular diseases, has become effective.
- 07 Jul 2016 Status changed from planning to not yet recruiting, according to an Eleven Biotherapeutics media release.
- 13 Jun 2016 According to an Eleven Biotherapeutics media release, the company has submitted an IND application to the US FDA.